Skip to main content

Table 2 The results of the univariate analyses of factors predicting the survival rates

From: Concurrent hyperfractionated chemoradiotherapy for head and neck squamous cell carcinoma: the prognostic impact of the overall treatment time and completion rates of chemotherapy

  n Local control Disease-free survival Distant metastasis-free survival Overall survival
3-year (%) p 3-year (%) p 3-year (%) p 3-year (%) p
Age (years)    0.41   0.44   0.81   0.82
 <65 33 72   67   87   79  
 ≥65 36 62   59   91   70  
PS    0.73   0.63   0.83   0.34
 0–1 59 68   64   87   77  
 2–3 10 64   58   100   61  
Clinical stage    0.007   0.0009   0.01   <0.0001
 I–II 35 84   84     100  
 III–IV 34 50   39     49  
Tumor stage    <0.0001   <0.0001   0.17   <0.0001
 T1–2 55 79   74   80   87  
 T3–4 14 23   17   90   34  
N stage    0.05   0.0091   0.01   0.0012
 N0 38 77   77   97   94  
 N1–3 31 54   43   76   52  
Overall treatment (days) 0.039   0.015   0.11   0.02
 ≤48 45 78   74   91   84  
 ≥49 24 48   41   85   56  
Days of RT without carboplatin 0.69   0.61   0.82   0.21
 ≤5 40 68   64   83   80  
 ≥6 29 64   41   95   67  
Hemoglobin at the start of RT (g/dl) 0.30   0.22   0.66   0.02
 <12 18 51   44   83   57  
 ≥12 51 71   68   92   82